HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative from Patient Medical Records in The Gulf Cooperation Council

Study identifier:D133FR00197

ClinicalTrials.gov identifier:NCT06125314

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Multicenter, Non-Interventional, Retrospective Study Aims to Estimate the Prevalence and Describe the Clinical Manifestations of HER2-Low Breast Cancer Reported in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2- Negative from Patient Medical Records in The Gulf Council Cooperation Region

Medical condition

Breast Neoplasms

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

Female

Estimated Enrollment

385

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 05 Mar 2024
Estimated Primary Completion Date: 31 Dec 2024
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria